Lucy Roberts
Family · Lake Mary, FLNPI 1275642043
Payments from drug & device makers
Across 160 payments — averaging $16.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insulet Corporation$580
- Abbott$402
- Sanofi-aventis U.S. LLC$271
- Xeris Pharmaceuticals, Inc.$203
- Lilly USA, LLC$125
- Boehringer Ingelheim$116
- plus $1K from 24 others
What the payments were for
- Food & beverage$2,706100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insulet Corporation | 48 | $580 |
| Abbott | 20 | $402 |
| Sanofi-aventis U.S. LLC | 13 | $271 |
| Xeris Pharmaceuticals, Inc. | 10 | $203 |
| Lilly USA, LLC | 5 | $125 |
| Boehringer Ingelheim | 6 | $116 |
| Medtronic | 5 | $105 |
| AstraZeneca | 4 | $77 |
| Esperion Therapeutics, Inc. | 3 | $77 |
| Cequr Corporation | 5 | $74 |
| AbbVie | 4 | $72 |
| Amarin Pharma, Inc. | 3 | $60 |
| Antares Pharma, Inc. | 4 | $56 |
| Dexcom, Inc. | 3 | $55 |
| Bayer | 3 | $54 |
| IBSA Pharma Inc. | 2 | $39 |
| Tandem Diabetes Care, Inc. | 2 | $38 |
| Amneal Pharmaceuticals LLC | 3 | $37 |
| Novo Nordisk | 2 | $34 |
| Zealand Pharma US, Inc. | 2 | $33 |
| Vistapharm, Inc. | 2 | $31 |
| Acerus Pharmaceuticals Corporation | 2 | $29 |
| Radius Health, Inc. | 1 | $24 |
| Ultragenyx Pharmaceutical Inc. | 1 | $21 |
| Merck | 1 | $18 |
| Clarus Therapeutics Inc. | 2 | $18 |
| GRT US Holding, Inc. | 1 | $16 |
| Mannkind Corporation | 1 | $16 |
| Lifescan, Inc. | 1 | $16 |
| Corcept Therapeutics | 1 | $12 |
How this compares
$2,712 in reported general payments places this provider in the 85th percentile of 14,618 family providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 126 | $57,625 |
| TrulicityDulaglutide | 42 | $51,811 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 22 | $29,385 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 14 | $29,012 |
| TradjentaLinagliptin | 88 | $28,823 |
| RybelsusSemaglutide | 24 | $25,911 |
| MounjaroTirzepatide | 24 | $25,500 |
| JanuviaSitagliptin Phosphate | 60 | $20,139 |
| OzempicSemaglutide | 11 | $19,159 |
| Tresiba Flextouch U-100Insulin Degludec | 35 | $17,797 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 85 | $12,783 |
| Novolog FlexpenInsulin Aspart | 44 | $9,784 |
| NovologInsulin Aspart | 22 | $9,186 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 146 | $6,941 |
| Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp | 12 | $6,700 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $116 | $86,448214 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog, Insulin Lispro | $125 | $81,429128 claims |
| Novo NordiskRybelsus, Ozempic, Novolog, Novolog Mix 70-30 | $34 | $60,34468 claims |
| MerckJanuvia | $18 | $20,13960 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $37 | $3,170221 claims |
| Sanofi-aventis U.S. LLCLantus | $271 | $3,05127 claims |
| AbbVieSynthroid | $72 | $97419 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 14,618 family providers in Florida.
Other family in Lake Mary
- John HuffakerVenice$8M
- Stephanie MompointMiami$4.5M
- Miguel TrujilloMiami Gardens$4.4M
- Itsel Cardenas RamonMiami$1M
- Lewis HarringtonTampa$954K
- Adam StrosbergFort Lauderdale$859K
- Danielle PharesFt Lauderdale$713K
- David RodriguezHialeah$658K
- Donna OrtizOrlando$417K
- Patrick SzarazMiami$327K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.